VICOR CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VICOR CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $452.70M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $359.06M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $405.06M | Mar 2, 2026 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $407.70M | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | $407.70M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $359.06M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $405.06M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $399.08M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $359.36M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $84.30M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $78.11M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $70.76M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $63.40M | Mar 1, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $58.77M | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | $56.89M | Mar 9, 2018 |
| FY2017 | Jun 30, 2017 | $57.71M | Mar 9, 2018 |
| FY2017 | Mar 31, 2017 | $54.46M | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | $48.09M | Mar 9, 2018 |
| FY2017 | Sep 30, 2016 | $53.23M | Mar 9, 2018 |
| FY2017 | Jun 30, 2016 | $52.94M | Mar 9, 2018 |
| FY2017 | Mar 31, 2016 | $46.03M | Mar 9, 2018 |
| FY2016 | Dec 31, 2015 | $51.39M | Mar 7, 2017 |
| FY2016 | Sep 30, 2015 | $48.66M | Mar 7, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $259.43M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $184.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $204.93M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $180.56M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $178.20M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $40.45M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $33.35M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $30.32M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $27.33M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $29.76M | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.56M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $6.13M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $53.60M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $25.45M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $56.63M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $11.19M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $5.79M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $2.67M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($1.74M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $1.31M | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.83M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($1.31M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $51.36M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $27.20M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $55.60M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $17.37M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $13.82M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $32.06M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($1.36M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($6.31M) | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.57M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $68.92M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $67.86M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $60.59M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $53.11M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $50.92M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $46.59M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $44.29M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $44.92M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $41.85M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $99.03M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $96.89M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $85.71M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $86.26M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $69.48M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $63.16M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $62.56M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $62.22M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $58.09M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $55.68M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $139.55M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $50.84M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $74.53M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $22.94M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $54.44M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $34.74M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $22.21M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $36.17M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($2.46M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $544.0K | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.32M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $23.60M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $33.45M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $63.97M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $47.76M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $28.65M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $12.49M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $18.21M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $12.55M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $8.43M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $785.83M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $641.12M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $594.89M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $536.90M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $477.21M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $396.24M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $240.73M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $221.07M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $165.72M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $154.07M | Feb 28, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.02M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $70.83M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $53.78M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $72.57M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $53.30M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $45.08M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $34.86M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $36.98M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $29.31M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $23.05M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $711.56M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $570.07M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $540.87M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $464.09M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $423.60M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $350.82M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $205.56M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $183.66M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $136.11M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $130.81M | Mar 9, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $421.36M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $302.80M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $296.67M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $243.08M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $217.63M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $161.01M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $143.10M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $129.00M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $93.61M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $93.44M | Mar 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $402.81M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $277.27M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $242.22M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $190.61M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $182.42M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $161.74M | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | $84.67M | Mar 1, 2022 |
| FY2021 | Dec 31, 2018 | $70.56M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $44.23M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $56.17M | Feb 28, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 1, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 1, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | 11.76M | Feb 28, 2023 |
| FY2013 | Dec 31, 2013 | 26.78M | Mar 14, 2014 |
| FY2013 | Dec 31, 2012 | 30.04M | Mar 14, 2014 |
| FY2012 | Dec 31, 2011 | 30.04B | Mar 7, 2013 |
| FY2011 | Dec 31, 2010 | 30.00M | Mar 2, 2012 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $6.27M | Mar 2, 2012 |
| FY2011 | Dec 31, 2010 | $12.51M | Mar 2, 2012 |